A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.
born between 25 0/7 and 29 6/7 weeks of gestation
less than 48 hours of age at first lipid dose (The cohort is defined by gestational age rather than birth weight to avoid an over-represented sample of growth-restricted infants in birth weight defined cohorts.)
serious congenital anomalies
conditions at birth that will require surgery prior to discharge
imminent death such that withdrawal of intensive care support is anticipated within the first 72 hours after birth
The University of Texas Health Science Center at San Antonio
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator